Aptevo Therapeutics Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Aptevo Therapeutics Inc. (APVO) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $23.51 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- Aptevo Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $23.51M.
- Aptevo Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$53.84M, a 1340.29% decline year-over-year.
- Aptevo Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $65.36M.
- Aptevo Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $20.77M.
- Aptevo Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $29.46M.
- Aptevo Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$47.39M.
- Aptevo Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$1.53M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | $23.51M 10-Q · filed 2018-05-10 | -$30.33M derived: sum of 2 quarters · filed 2018-05-10 | $35.03M derived: sum of 3 quarters · filed 2018-05-10 | $55.80M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | -$53.84M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | $11.52M derived: sum of 2 quarters · filed 2018-03-13 | $32.29M derived: sum of 3 quarters · filed 2018-03-13 | $29.46M 10-K · filed 2018-03-13 |
| 2017-09-30 | $65.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $86.13M derived: sum of 2 quarters · filed 2017-11-13 | $83.30M 10-Q · filed 2017-11-13 | $87.64M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | $20.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $17.94M 10-Q · filed 2017-08-10 | $22.28M derived: sum of 3 quarters · filed 2018-05-10 | -$27.48M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | -$2.83M 10-Q · filed 2018-05-10 | $1.51M derived: sum of 2 quarters · filed 2018-05-10 | -$48.24M derived: sum of 3 quarters · filed 2018-05-10 | -$49.15M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-13 | -$45.41M derived: sum of 2 quarters · filed 2018-03-13 | -$46.32M derived: sum of 3 quarters · filed 2018-03-13 | -$47.39M 10-K · filed 2018-03-13 |
| 2016-09-30 | -$49.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | -$50.66M derived: sum of 2 quarters · filed 2017-11-13 | -$51.73M 10-Q · filed 2017-11-13 | -$52.25M derived: sum of 4 quarters · filed 2017-11-13 |
| 2016-06-30 | -$908.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$1.98M 10-Q · filed 2017-08-10 | -$2.49M derived: sum of 3 quarters · filed 2017-08-10 | -$2.93M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | -$1.07M 10-Q · filed 2017-05-12 | -$1.59M derived: sum of 2 quarters · filed 2017-05-12 | -$2.02M derived: sum of 3 quarters · filed 2017-05-12 | |
| 2015-12-31 | -$515.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | -$953.00K derived: sum of 2 quarters · filed 2017-03-31 | -$1.53M 10-K · filed 2017-03-31 | |
| 2015-09-30 | -$438.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2016-11-14 | -$1.01M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$574.00K 10-Q/A · filed 2016-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |